Please ensure Javascript is enabled for purposes of website accessibility

The Biggest Threat to Repligen Stock

By Keith Speights - Apr 29, 2016 at 8:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The bioprocessing leader's business looks solid, but here's one major risk for Repligen.

Image source: Repligen.

Last year demonstrated both the promise and the peril associated with investing in shares of Repligen Corporation (RGEN 1.82%). By late May, the bioprocessing leader's stock had doubled. By the end of 2015, most of those gains had vaporized. Repligen's downtrend continued through early February of this year, but the stock is now on a roll -- up around 30% over the past two-and-a-half months.

Despite this solid rebound, risks remain for Repligen. One threat in particular holds the biggest potential to derail this once high-flying stock.

Plenty of positives
There's a lot to like about Repligen. The company's balance sheet looks impressive, with no debt and nearly $72 million in cash. Revenue in 2015 jumped 38% year over year. Earnings grew 14% on a GAAP basis compared to the prior year. That growth, while solid, was heavily weighted by the impact of Repligen's acquisition of Refine Technology. On an adjusted non-GAAP basis, 2015 earnings increased by 69%.

Repligen expects to turn in a good performance in 2016 also. The company projects revenue growth between 11% and 15%. Even better, Repligen thinks that earnings for this year will come in more than 70% higher than its 2015 results.

Are these expectations realistic? Probably so. Around half of Repligen's revenue stems from its protein A ligands business. That business continues to look promising, thanks to growth in the monoclonal antibody (mAb) market. Last year, the FDA approved a record nine mAb drugs. More could be on the way in the next few years, with mAbs representing the fastest-growing segment of the biologics market.

Repligen's protein A ligands dominance seems to be pretty secure. In February, the company extended its supply agreement with GE Healthcare (GE 0.01%) for the Lund, Sweden, manufacturing facility through 2019. The contract with GE for Repligen's Waltham, Mass., facility doesn't expire until 2021. GE Healthcare is Repligen's largest customer and accounted for 37% of Repligen's total revenue last year.

The biggest growth area for the company, though, comes from the alternating tangential flow (ATF) filtration business picked up in the 2014 acquisition of Refine Technology. Repligen's ATF sales soared over 40% in 2015 compared to the previous year. This technology appears to be an emerging industry standard for biologics manufacturers and should continue to generate significant revenue for the company. 

The biggest threat
All things considered, Repligen seems to be in good shape. Its core protein A ligands business is thriving. The company locked up a long-term supply deal with GE Healthcare. And it has a great new growth area with ATF filtration. What could go wrong?

The biggest threat for Repligen isn't related to the company's underlying business. Instead, the real risk is related to Repligen's stock price, and that risk is a direct result of the company's success.

Even though Repligen's shares remain well below the highs from mid-2015, the stock still has a sky-high valuation. Repligen currently trades at a trailing 12-month earnings multiple of just under 100. Its forward earnings multiple of 45 looks less scary but is still high.

This kind of premium valuation means that Repligen's stock will pay the price of any misstep. And even if the company itself doesn't stumble, outside factors can still cause problems. We saw this happen in the third quarter last year when Repligen's numbers looked great but a Wall Street analyst downgrade caused shares to plunge 20%.

Digging into that analyst downgrade illustrates the challenge for Repligen. The company made a decision to not move forward with the launch of a new protein A resin. Repligen's rationale was that there were better places to allocate resources that could be more profitable. Although the decision could very well prove to be a smart move, it still hurt Repligen's stock because one analyst thought the company's growth prospects were diminished.

Looking ahead
What does the future hold for Repligen? There's a high likelihood for sustained business success. The prevalence of biologics will increase -- driving more demand for the protein A ligands supplied by Repligen. Likewise, ATF filtration should also continue to be a high-growth business for the company.

Investors, though, could still experience a roller-coaster ride. Repligen's shares could keep the rebound going, especially if the broader market continues its rally. However, the slightest bump in the road is likely to knock the stock's price down considerably. The higher the valuation, the harder the fall.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Repligen Corporation Stock Quote
Repligen Corporation
$154.18 (1.82%) $2.75
General Electric Company Stock Quote
General Electric Company
$74.53 (0.01%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.